Summit Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 14.72 million compared to USD 16.77 million a year ago. Basic loss per share from continuing operations was USD 0.02.
For the six months, net loss was USD 557.09 million compared to USD 38.17 million a year ago. Basic loss per share from continuing operations was USD 1.03.